Clinical Trial

Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

Study acronym: PPDUO
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated June 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
The PPOS protocol (Progestin-primed Ovarian Stimulation) involves avoiding ovulation during ovarian stimulation with progesterone. It is a reliable and safe protocol that has been widely used in recent years for in vitro fertilization, as it reduces the number of injections needed during controlled ovarian stimulation and is more cost-effective for patients. The aim of this study is to compare two methods of ovarian stimulation for in vitro fertilization: the PPOS protocol (Group A) and the conventional protocol with injected antagonists (Group B). The goal is to determine whether both methods are equally effective in obtaining euploid embryos in the context of double ovarian stimulation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-09.
Trial Details
NCT Number NCT06637189
Lead Sponsor Ginefiv
Collaborators: Theramex
Conditions Stimulation in the Ovary, Embryo, Oocyte, Oocyte Retrieval, Fertilization in Vitro, Blastocyst, PGT-A
Enrollment 144 participants
Start Date 2024-10-15
Primary Completion 2025-06-15 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-15